Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.

MLA

Fukuda, Masaki, et al. “Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.” Clinical Drug Investigation, vol. 44, no. 7, July 2024, pp. 527–40. EBSCOhost, https://doi.org/10.1007/s40261-024-01376-w.

APA

Fukuda, M., Hattori, J., Ohkubo, R., Watanabe, A., & Maekawa, S. (2024). Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan. Clinical Drug Investigation, 44(7), 527–540. https://doi.org/10.1007/s40261-024-01376-w

Chicago

Fukuda, Masaki, Junko Hattori, Rika Ohkubo, Asuka Watanabe, and Shinichiroh Maekawa. 2024. “Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.” Clinical Drug Investigation 44 (7): 527–40. doi:10.1007/s40261-024-01376-w.